FDA panel reviews 1st new Alzheimer’s drug in 2 decades
A panel of outside experts meets Friday to advise the Food and Drug Administration on aducanumab, a drug from Cambridge, Massachusetts-based Biogen Inc. and Japan’s Eisai Co. FDA doesn’t always follow the panel’s advice but usually does and has until March to decide.
Best Dslr Camera under 200 via FOX BUSINESS NEWS Markets
https://ift.tt/38f7cTK
0 Comments:
Post a Comment